News

Investor's Business Daily on MSN1d
Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments
Sarepta stock soared after the FDA said the biotech company can resume shipments of a controversial gene therapy drug.
President Says Epstein Friendship Ended Over ‘Stolen’ Worker
F.D.A. resignation: The Food and Drug Administration’s top vaccine and gene therapy official resigned on Tuesday after a ...
Sarepta will resume gene therapy shipments after FDA review of recent patient death
Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy ...
Sarepta Shares Fall After Gene Therapy Hits Another Regulatory Roadblock
Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the ...
Precision Medicine Online6d
Sarepta Halts Duchenne Gene Therapy Sales Amid FDA Scrutiny, Raising Concerns Over Financial Future
Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.
BioPharma Dive6d
Rocket lays off staff; Abivax capitalizes on immune drug data
The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.
Wicked Local7d
Cambridge biopharmaceutical company lays off nearly 500 workers
This Massachusetts-based biopharmaceutical company announced hundreds of layoffs last week. Here's what the CEO said about it ...
Makary ally named to key FDA drug post
Dr. George Tidmarsh, a Stanford pediatrics adjunct professor and former pharmaceutical executive, is FDA Commissioner Marty ...
BioSpace8d
Lack of Transparency Tarnishes Sarepta’s Sheen as Patient Deaths Trigger FDA Battle
Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, ...
Clinical Trials Arena8d
Sarepta refuses to pull gene therapy despite FDA request
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.
Sarepta Therapeutics cuts Durham jobs amid mass layoffs, FDA scrutiny
A Massachusetts biotechnology company is laying off 21 employees in Durham amid a broader restructuring and pressure from federal regulators.
GSK to lay off 150 Cambridge employees
British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...